Service Tax Additional
select a format
Recent Viewed Reports
Why Ken Reasearch?
While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"
We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"
The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"
Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"
We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"
Dyslipidemia-Current and Future Players
GlobalData has released its pharma report, "Dyslipidemia-Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dyslipidemia Market. The report identifies and analyses the key companies shaping and driving the global Dyslipidemia market. The report provides insight into the competitive Dyslipidemia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Investigation of current and future market competition for Dyslipidemia
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of Dyslipidemia sector through market impact analysis, future market scenario and company analysis
Reasons To Buy
Gain a high level view of the trends shaping and driving Dyslipidemia market
Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
Create an effective counter-strategy to gain a competitive advantage against those currently in the market
What's the next big thing in the global Dyslipidemia market landscape? Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 8
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers-Global Issues 18
4 Current and Future Players 22
4.1 Overview 22
4.2 Trends in Corporate Strategy 27
4.3 Company Profiles 29
4.3.1 AbbVie 29
4.3.2 Aegerion Pharmaceuticals, Inc. 31
4.3.3 Amarin 33
4.3.4 Amgen 35
4.3.5 AstraZeneca 37
4.3.6 Cerenis Therapeutics Inc. 40
4.3.7 Daiichi Sankyo 42
4.3.8 Dezima Pharma 44
4.3.9 Eli Lilly 46
4.3.10 Esperion Therapeutics, Inc. 49
4.3.11 Genzyme 51
4.3.12 GlaxoSmithKline 53
4.3.13 Merck & Co. 55
4.3.14 Pfizer 58
4.3.15 Regeneron Pharmaceuticals, Inc. 60
4.3.16 Sanofi 62
5 Appendix 66
5.1 Bibliography 66
5.2 Abbreviations 94
5.3 Methodology 102
5.4 Forecasting Methodology 102
5.4.1 Diagnosed Dyslipidemia Patients 102
5.4.2 Percent Drug-Treated Patients 103
5.4.3 Drugs Included in Each Therapeutic Class 103
5.4.4 Launch and Patent Expiry Dates 104
5.4.5 General Pricing Assumptions 105
5.4.6 Individual Drug Assumptions 106
5.4.7 Generic Erosion 113
5.4.8 Pricing of Pipeline Agents 113
5.5 Physicians and Specialists Included in this Study 115
5.6 About the Authors 117
5.6.1 Analyst 117
5.6.2 Therapy Area Director 117
5.6.3 Epidemiologist 118
5.6.4 Global Head of Healthcare 118
5.7 About GlobalData 119
5.8 Disclaimer 119
1.2 List of Figures
Figure 1: Global Sales for Dyslipidemia by Country, 2013-2023 14
Figure 2: Global Sales for Dyslipidemia by Drug Class, 2013-2023 15
Figure 3: Global Sales Forecast for PCSK9 mAbs, 2015-2023 16
Figure 4: Projected Global Sales of Dyslipidemia Drugs by Year, 2013-2023 17
Figure 5: Global Sales of Branded Products for Dyslipidemia by Company, 2013-2023 26
Figure 6: Company Portfolio Gap Analysis in Dyslipidemia, 2013-2023 27
1.1 List of Tables
Table 1: Global Sales Forecasts (USD m) for Dyslipidemia, 2013-2023 12
Table 2: Dyslipidemia Market-Drivers and Barriers, 2014 18
Table 3: Key Companies in the Dyslipidemia Market in the 8MM, 2014 25
Table 4: AbbVie's Dyslipidemia Portfolio Assessment, 2014 30
Table 5: Aegerion's Dyslipidemia Portfolio Assessment, 2014 32
Table 6: Amarin's Dyslipidemia Portfolio Assessment, 2014 34
Table 7: Amgen's Dyslipidemia Portfolio Assessment, 2014 36
Table 8: AstraZeneca's Dyslipidemia Portfolio Assessment, 2014 39
Table 9: Cerenis' Dyslipidemia Portfolio Assessment, 2014 41
Table 10: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2014 43
Table 11: Dezima's Dyslipidemia Portfolio Assessment, 2014 45
Table 12: Eli Lilly's Dyslipidemia Portfolio Assessment, 2014 47
Table 13: Esperion's Dyslipidemia Portfolio Assessment, 2014 50
Table 14: Genzyme's Dyslipidemia Portfolio Assessment, 2014 52
Table 15: GlaxoSmithKline's Dyslipidemia Portfolio Assessment, 2014 54
Table 16: Merck's Dyslipidemia Portfolio Assessment, 2014 57
Table 17: Pfizer's Dyslipidemia Portfolio Assessment, 2014 59
Table 18: Regeneron's Dyslipidemia Portfolio Assessment, 2014 61
Table 19: Sanofi's Dyslipidemia Portfolio Assessment, 2014 64
Table 20: Key Launch Dates 104
Table 21: Key Patent Expiries 104
Table 22: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 116
Single User License:
Corporate User License:
Aegerion Pharmaceuticals, Inc.
Cerenis Therapeutics Inc.
Esperion Therapeutics, Inc.
Merck & Co.
Regeneron Pharmaceuticals, Inc.